8-K: InMed Pharmaceuticals Selects Intravitreal Formulation for INM-089 in Dry AMD Treatment

InMed Pharmaceuticals has announced the selection of an intravitreal formulation for its drug candidate INM-089, targeting the treatment of dry age-related macular degeneration (AMD).

Summary

• InMed Pharmaceuticals has chosen an intravitreal (IVT) formulation for INM-089 to treat dry age-related macular degeneration (AMD).
• The IVT formulation has shown successful delivery in preclinical studies at doses up to 10 times the projected therapeutic level, indicating a favorable safety margin.
• Dose-ranging studies have been completed to guide the selection of appropriate doses for pivotal preclinical toxicology studies.
• Intravitreal injection is the standard method for delivering drugs to the back of the eye, which is important for treating AMD.
• Dry AMD affects an estimated 196 million people worldwide, with 80% of AMD cases being dry AMD.
• There is a significant unmet medical need for dry AMD treatments, impacting an estimated 12.6% of Americans aged 40 and over.
• INM-089 has demonstrated improvements in preclinical studies, including neuroprotection of photoreceptors and reduction of extracellular deposits.

Sentiment

Score: 7

Explanation: The document presents positive news regarding the selection of a drug formulation and promising preclinical results, but it also acknowledges the inherent risks and uncertainties in drug development. The sentiment is cautiously optimistic.

Positives

• The selection of an IVT formulation for INM-089 is a positive step in the development of a treatment for dry AMD.
• Successful delivery of the IVT formulation at high doses in preclinical studies suggests a strong safety profile.
• The completion of dose-ranging studies will help guide the selection of appropriate doses for future studies.
• INM-089 has demonstrated promising results in preclinical studies, showing improvements in key markers of dry AMD.
• The company is using the established method of intravitreal injection for drug delivery.

Risks

• The development of INM-089 is still in the preclinical stage, and there is no guarantee of success in clinical trials.
• The company faces risks and uncertainties that could cause actual results to differ materially from forward-looking statements.
• There are known and unknown risk factors that could impact the company's performance.

Future Outlook

The company plans to use the INM-089 IVT formulation in the next stages of preclinical studies, including GLP-enabling studies and subsequent stages of clinical development. The information from the dose-ranging study will guide the selection of appropriate doses for the pivotal preclinical toxicology studies.

Management Comments

• Michael Woudenberg, InMed's Chief Operating Officer, stated that they are encouraged by the data demonstrating successful delivery of INM-089 as an IVT formulation.
• He also noted that the data underscores the potential of the IVT formulation as an effective therapeutic approach for dry AMD.

Industry Context

The announcement is relevant to the broader pharmaceutical industry's focus on developing treatments for age-related macular degeneration, a significant unmet medical need. The selection of an intravitreal formulation aligns with the standard of care for delivering drugs to the back of the eye.

Comparison to Industry Standards

• The use of intravitreal injection for drug delivery is consistent with industry standards for treating retinal diseases, similar to approaches used by companies like Regeneron with Eylea and Roche with Lucentis.
• The focus on small molecule drug candidates is a common approach in pharmaceutical development, with companies like Alcon and Novartis also exploring similar strategies.
• The preclinical results showing improvements in photoreceptor function and reduction of extracellular deposits are comparable to the goals of other companies developing treatments for dry AMD, such as Apellis Pharmaceuticals with Syfovre.

Stakeholder Impact

• Shareholders may view this announcement positively as it represents progress in the company's drug development pipeline.
• Patients with dry AMD may see this as a potential future treatment option.
• Employees may be encouraged by the progress of the company's research and development efforts.

Next Steps

• The INM-089 IVT formulation will be used in the next stages of preclinical studies.
• GLP-enabling studies will be conducted.
• Subsequent stages of clinical development will follow.
• The information from the dose-ranging study will guide the selection of appropriate doses for the pivotal preclinical toxicology studies.

Key Dates

Keywords

INM-089, Intravitreal, Dry AMD, Age-related Macular Degeneration, Ophthalmology, Drug Development, Pharmaceuticals, Retinal, Therapeutic